{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T10:57:11Z","timestamp":1776855431473,"version":"3.51.2"},"reference-count":31,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To investigate the factors associated with maximum visual improvement (peak vision) gain and the risk factors of peak vision loss and multiple recurrences in myopic macular neovascularization undergoing antivascular endothelial growth factor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Retrospective study of 310 eyes with active myopic macular neovascularization and median follow-up of 3.5 years. We defined peak vision gain as the maximum best-corrected visual acuity value reached under treatment and peak vision loss as best-corrected visual acuity never scoring as peak vision. We used multiple-event Prentice, Williams, and Peterson models to compute recurrences' incidence and Cox regression to identify risk factors for peak vision gain, peak vision loss, and multiple recurrences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Eyes with worse baseline best-corrected visual acuity {hazard ratio (HR) = 2.59 (95% confidence interval [CI]: 1.63\u20134.11) for 0.1 logMAR increase, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001} had higher chance to achieve peak vision. Peak vision was lost in 162 eyes (52%). Older age (HR = 1.22 [95% CI: 1.02\u20131.43] for 10-year increase, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02) and recurrences (HR = 1.10 [95% CI: 1.01\u20131.22] for event, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04) predicted nonsustained peak vision. Older age (HR = 1.13 [95% CI: 1.04\u20131.27] for 10-year increase, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.006), larger myopic macular neovascularization (HR = 1.06 [95% CI: 1.01\u20131.13] for 1-mm<jats:sup>2<\/jats:sup> increase, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.04), and juxtafoveal location (HR = 1.88 [95% CI: 1.28\u20132.77] vs. extrafoveal, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.001) predicted multiple recurrences.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Myopic macular neovascularization eyes lose vision mainly because of multiple recurrences. Patients at risk for recurrences should undergo more attentive monitoring to avoid vision loss.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003673","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T23:00:05Z","timestamp":1668207605000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["RISK FACTORS OF VISION LOSS AND MULTIPLE RECURRENCES IN MYOPIC MACULAR NEOVASCULARIZATION"],"prefix":"10.1097","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2938-0409","authenticated-orcid":false,"given":"Maria Vittoria","family":"Cicinelli","sequence":"first","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"},{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"L T De Felice","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lamberto","family":"La Franca","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"},{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Rabiolo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Marchese","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"},{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Battaglia Parodi","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"},{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo","family":"Introini","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Bandello","sequence":"additional","affiliation":[{"name":"School of Medicine, Vita-Salute San Raffaele University, Milan, Italy; and"},{"name":"Department of Ophthalmology, IRCCS San Raffaele Scientific Institute, Milan, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250605","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","article-title":"Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review","volume":"157","author":"Wong","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R2-20250605","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.ophtha.2009.11.003","article-title":"Long-term pattern of progression of myopic maculopathy: a natural history study","volume":"117","author":"Hayashi","year":"2010","journal-title":"Ophthalmology"},{"key":"R3-20250605","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1016\/j.ophtha.2013.06.010","article-title":"Ranibizumab in myopic choroidal neovascularization: the 12-month results from the REPAIR study","volume":"120","author":"Tufail","year":"2013","journal-title":"Ophthalmology"},{"key":"R4-20250605","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"R5-20250605","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","article-title":"Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study","volume":"122","author":"Ikuno","year":"2015","journal-title":"Ophthalmology"},{"key":"R6-20250605","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1097\/IAE.0000000000000610","article-title":"Factors influencing need for retreatment and long-term visual outcome after intravitreal bevacizumab for myopic choroidal neovascularization","volume":"35","author":"Ng","year":"2015","journal-title":"Retina"},{"key":"R7-20250605","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1097\/IAE.0000000000001453","article-title":"Five-year outcomes of intravitreal injection of ranibizumab for the treatment of myopic choroidal neovascularization","volume":"37","author":"Wu","year":"2017","journal-title":"Retina"},{"key":"R8-20250605","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/IAE.0000000000002164","article-title":"Five-year outcomes of intravitreal ranibizumab for choroidal neovascularization in patients with pathologic myopia","volume":"39","author":"Onishi","year":"2019","journal-title":"Retina"},{"key":"R9-20250605","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1097\/IAE.0b013e318285cc24","article-title":"Ocular risk factors for recurrence of myopic choroidal neovascularization: long-term follow-up study","volume":"33","author":"Kang","year":"2013","journal-title":"Retina"},{"key":"R10-20250605","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/bjophthalmol-2014-305131","article-title":"Myopic choroidal neovascularisation: current concepts and update on clinical management","volume":"99","author":"Wong","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R11-20250605","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.oret.2017.08.019","article-title":"Tomographic biomarkers predicting progression to fibrosis in treated neovascular age-related macular degeneration: a multimodal imaging study","volume":"2","author":"Casalino","year":"2018","journal-title":"Ophthalmol Retina"},{"key":"R12-20250605","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ajo.2015.01.022","article-title":"International photographic classification and grading system for myopic maculopathy","volume":"159","author":"Ohno-Matsui","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R13-20250605","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1080\/00401706.1995.10484300","article-title":"Some simple robust methods for the analysis of recurrent events","volume":"37","author":"Lawless","year":"1995","journal-title":"Technometrics"},{"key":"R14-20250605","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"R15-20250605","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1097\/IAE.0000000000000632","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to pathologic myopia: six years outcome","volume":"35","author":"Ruiz-Moreno","year":"2015","journal-title":"Retina"},{"key":"R16-20250605","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1097\/IAE.0000000000001313","article-title":"Six-year outcomes of intravitreal bevacizumab for choroidal neovascularization in patients with pathologic myopia","volume":"37","author":"Kasahara","year":"2017","journal-title":"Retina"},{"key":"R17-20250605","first-page":"1132","article-title":"Three-year OCT predictive factors of disease recurrence in eyes with successfully treated myopic choroidal neovascularisation","volume":"106","author":"Borrelli","year":"1020","journal-title":"Br J Ophthalmol"},{"key":"R18-20250605","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: a mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"R19-20250605","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1471-2288-14-133","article-title":"Bias in the study of prediction of change: a Monte Carlo simulation study of the effects of selective attrition and inappropriate modeling of regression toward the mean","volume":"14","author":"Gustavson","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R20-20250605","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1001\/jamaophthalmol.2020.5044","article-title":"Insights from survival analyses during 12 years of anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration","volume":"139","author":"Fu","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R21-20250605","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1097\/IAE.0000000000001436","article-title":"Factors influencing visual acuity in patients receiving anti-vascular endothelial growth factor for myopic choroidal neovascularization","volume":"37","author":"Iacono","year":"2017","journal-title":"Retina"},{"key":"R22-20250605","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.ajo.2010.09.021","article-title":"Intravitreal ranibizumab for myopic choroidal neovascularization: factors predictive of visual outcome and need for retreatment","volume":"151","author":"Calvo-Gonzalez","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R23-20250605","doi-asserted-by":"crossref","first-page":"e0227557","DOI":"10.1371\/journal.pone.0227557","article-title":"Real-world effectiveness and safety of ranibizumab for the treatment of myopic choroidal neovascularization: results from the LUMINOUS study","volume":"15","author":"Hamilton","year":"2020","journal-title":"PLoS One"},{"key":"R24-20250605","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/aos.14893","article-title":"Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry","volume":"100","author":"Gabrielle","year":"2022","journal-title":"Acta Ophthalmologica"},{"key":"R25-20250605","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ajo.2013.08.002","article-title":"Prognostic factors of eyes with naive subfoveal myopic choroidal neovascularization after intravitreal bevacizumab","volume":"156","author":"Yang","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R26-20250605","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000001384","article-title":"Choroidal thickness and chorioretinal atrophy in myopic choroidal neovascularization with anti-vascular endothelial growth factor therapy","volume":"37","author":"Lee","year":"2017","journal-title":"Retina"},{"key":"R27-20250605","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/j.ophtha.2015.06.053","article-title":"Factors associated with recurrence of age-related macular degeneration after anti-vascular endothelial growth factor treatment: a retrospective cohort study","volume":"122","author":"Kuroda","year":"2015","journal-title":"Ophthalmology"},{"key":"R28-20250605","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10456-019-09679-9","article-title":"Revascularization after angiogenesis inhibition favors new sprouting over abandoned vessel reuse","volume":"22","author":"Mukwaya","year":"2019","journal-title":"Angiogenesis"},{"key":"R29-20250605","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/IAE.0000000000003290","article-title":"Relationship between myopic choroidal neovascularization activity and perforating scleral vessels in high myopia","volume":"42","author":"Ruiz-Medrano","year":"2022","journal-title":"Retina"},{"key":"R30-20250605","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1159\/000333213","article-title":"Long-term follow-up of myopic choroidal neovascularization treated with ranibizumab","volume":"227","author":"Franqueira","year":"2012","journal-title":"Ophthalmologica"},{"key":"R31-20250605","doi-asserted-by":"crossref","first-page":"101470","DOI":"10.1016\/j.clae.2021.101470","article-title":"Axial length and its relationship to refractive error in Chinese university students","volume":"45","author":"Fan","year":"2022","journal-title":"Cont Lens Anterior Eye"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003673","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T17:09:28Z","timestamp":1749143368000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003673","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}